Patrick S Sullivan1, Farah Mouhanna2, Robertino Mera3, Elizabeth Pembleton1, Amanda D Castel4, Chandni Jaggi1, Jeb Jones1, Michael R Kramer1, Pema McGuinness1, Scott McCallister3, Aaron J Siegler5. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA. 2. Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC; Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA. 3. Gilead Sciences, Foster City, CA. 4. Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC. 5. Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA.
Abstract
PURPOSE: Pre-exposure prophylaxis (PrEP) is a pillar of the US Department of Health and Human Services "Ending the HIV Epidemic" (EHE) initiative in 50 EHE jurisdictions (48 U.S. counties and two U.S. cities) and seven U.S. states with high numbers of HIV diagnoses rates in rural areas. Current data systems do not provide data on PrEP uptake in counties or cities. METHODS: We report on PrEP users at the county level. Data from a large, commercial pharmacy database were used; we applied the U.S. Census Bureau's method to allocate PrEP users within a ZIP3 into counties and validated the results. We report counts and rates of PrEP users in 2018 for all EHE jurisdictions. We used joinpoint regression to model the estimated annual percent change in PrEP use for each jurisdiction and state. RESULTS: 93,156 people in the 50 EHE jurisdictions used PrEP in 2018; 94% were men and 39% were aged 25-34 years. There was more than an 80-fold difference in the range of rates of PrEP use per 100,000 population among the EHE jurisdictions (range: 8-644 per 100,000 population; median 93 per 100,000 population). PrEP use increased from 2012 to 2018 in all EHE counties and states. At current rates of growth of PrEP use, 94% of EHE counties and jurisdictions will reach their National HIV/AIDS Strategy goals of a 500% increase in PrEP use in 2020. EHE states had less variation in rates of PrEP use (range: 29-51/100,000 population; median 32/100,000 population). CONCLUSIONS: At the outset of a major U.S. government program to reduce HIV infections, rates of PrEP use are highly variable among the 50 EHE jurisdictions. Data from commercial prescription databases will be a useful public resource to understand progress in promoting use of PrEP as part of the EHE initiative and evaluating progress in PrEP use across health jurisdictions.
PURPOSE: Pre-exposure prophylaxis (PrEP) is a pillar of the US Department of Health and Human Services "Ending the HIV Epidemic" (EHE) initiative in 50 EHE jurisdictions (48 U.S. counties and two U.S. cities) and seven U.S. states with high numbers of HIV diagnoses rates in rural areas. Current data systems do not provide data on PrEP uptake in counties or cities. METHODS: We report on PrEP users at the county level. Data from a large, commercial pharmacy database were used; we applied the U.S. Census Bureau's method to allocate PrEP users within a ZIP3 into counties and validated the results. We report counts and rates of PrEP users in 2018 for all EHE jurisdictions. We used joinpoint regression to model the estimated annual percent change in PrEP use for each jurisdiction and state. RESULTS: 93,156 people in the 50 EHE jurisdictions used PrEP in 2018; 94% were men and 39% were aged 25-34 years. There was more than an 80-fold difference in the range of rates of PrEP use per 100,000 population among the EHE jurisdictions (range: 8-644 per 100,000 population; median 93 per 100,000 population). PrEP use increased from 2012 to 2018 in all EHE counties and states. At current rates of growth of PrEP use, 94% of EHE counties and jurisdictions will reach their National HIV/AIDS Strategy goals of a 500% increase in PrEP use in 2020. EHE states had less variation in rates of PrEP use (range: 29-51/100,000 population; median 32/100,000 population). CONCLUSIONS: At the outset of a major U.S. government program to reduce HIV infections, rates of PrEP use are highly variable among the 50 EHE jurisdictions. Data from commercial prescription databases will be a useful public resource to understand progress in promoting use of PrEP as part of the EHE initiative and evaluating progress in PrEP use across health jurisdictions.
Authors: Chase A Cannon; Meena S Ramchandani; Susan Buskin; Julia Dombrowski; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2022-08-15 Impact factor: 3.771
Authors: Aaron J Siegler; C Christina Mehta; Farah Mouhanna; Robertino Mera Giler; Amanda Castel; Elizabeth Pembleton; Chandni Jaggi; Jeb Jones; Michael R Kramer; Pema McGuinness; Scott McCallister; Patrick S Sullivan Journal: Ann Epidemiol Date: 2020-04-03 Impact factor: 3.797
Authors: Lorraine T Dean; Hsien-Yen Chang; William C Goedel; Philip A Chan; Jalpa A Doshi; Amy S Nunn Journal: AIDS Date: 2021-11-15 Impact factor: 4.177
Authors: Susan E Buskin; Richard J Lechtenberg; Francis A Slaughter; Joshua T Herbeck; Roxanne P Kerani; Matthew R Golden; Julia C Dombrowski Journal: PLoS One Date: 2022-08-29 Impact factor: 3.752
Authors: Patrick Sean Sullivan; Cory Woodyatt; Chelsea Koski; Elizabeth Pembleton; Pema McGuinness; Jennifer Taussig; Alexandra Ricca; Nicole Luisi; Eve Mokotoff; Nanette Benbow; Amanda D Castel; Ann N Do; Ronald O Valdiserri; Heather Bradley; Chandni Jaggi; Daniel O'Farrell; Rebecca Filipowicz; Aaron J Siegler; James Curran; Travis H Sanchez Journal: J Med Internet Res Date: 2020-10-23 Impact factor: 5.428